Uveal Melanoma Therapeutics Market Size, Share, and Industry Analysis, By Therapy (Chemotherapy, Targeted Therapy, and Immunotherapy), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Regional Forecast, 2025-2032

The global uveal melanoma therapeutics market is witnessing significant growth due to the increasing incidence of these cancer across the globe. Uveal melanoma, also known as ocular melanoma, is a rare form of cancer that originates in the uvea, the middle layer of the eye.

• According to estimates published by the American Cancer Society for 2024 in January 2024, an estimated 3,320 new cases of the melanomas of the eye and orbit is projected to occur in the U.S.

The market growth is further driven by the growing number of drug candidates in the pipeline. The rising governmental initiatives to increase cancer awareness among the population are expected to increase the rate of diagnosis and the demand for treatment over the forecast period.

Uveal Melanoma Therapeutics Market Driver

Diverse Technological Advancements to Boost the Market

Advancements in diagnostic technologies, such as optical coherence tomography (OCT) and ultrasound biomicroscopy, have improved early detection rates. Early diagnosis is critical, as it allows for timely intervention, which can significantly enhance treatment outcomes. The early detection and the development of innovative therapies, including immune checkpoint inhibitors and targeted biologics is expected to fuel the market growth. Additionally, promising pipeline and new approvals are expected to fuel the market growth in the near future.

• For instance, in May 2022, the FDA granted an orphan drug status to Darovasertib which is currently in the clinical trial. This pipelines are expected to result in new product launches and the market growth is expected.

Download Free sample to learn more about this report.

The above data shows average number of new eye cancer cases per year in the U.K. population. Overall, the U.K. had an incidence rate of 416 incidence per 100,000 population. Eye cancer accounts for less than 1% of all the new cancer cases in the U.K.

Uveal Melanoma Therapeutics Market Restraint

Side Effects Associated with Drugs Can Limit Market Growth

The side effects associated with these drugs can significantly hinder market growth for uveal melanoma treatments due to their impact on patient adherence and overall treatment experience. While oral chemotherapy offers convenience, it is accompanied by a range of challenges. Common side effects include nausea, vomiting, fatigue, and mouth sores, which can lead to complications such as bleeding gums and dry mouth. These adverse effects may discourage patients from continuing their treatment, ultimately limiting market expansion.

• For instance, a report by the CDC (Centers for Disease Control & Prevention) in August 2024 highlighted that cancer treatments can induce various side effects, including fatigue, eating difficulties, and depression. Such complications not only affect the patient's quality of life but also pose a barrier to consistent treatment adherence, thereby constraining market growth for uveal melanoma therapies.

Uveal Melanoma Therapeutics Market Opportunity

Promising Pipeline Drugs to Foster Future Market Growth

There is substantial potential for growth in the uveal melanoma therapeutics market, particularly in developing regions, despite facing challenges such as high treatment costs and limited access to healthcare services. Public health initiatives aimed at increasing awareness and promoting screening for uveal melanoma are essential, as they facilitate early detection and timely intervention. Such measures are expected to significantly drive market growth in these areas. Additionally, the market is expected to benefit from collaborations between pharmaceutical companies and local healthcare providers aimed at making innovative treatments more accessible.

• For instance, in June 2022, Immunocore Holdings plc announced clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK. Such collaborations expected to expand the therapeutics.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Uveal Melanoma, By Key Countries, 2023
• New Product Launches/ Approvals, By Key Players
• Pipeline Analysis, By Key Players
• Key Industry Development (Acquisitions, Mergers, Partnerships)
• Impact of COVID-19 on the Market

Analysis by Therapy

Based on therapy, the market is classified into chemotherapy drugs, targeted therapy drugs, and immunotherapy drugs.

The chemotherapy drugs segment holds a prominent market share, as they are widely used in the treatment of uveal melanoma. Additionally, their accessibility and relatively lower costs compared to other options drive their global market penetration.

• According to the American Cancer Society, chemotherapy serves as a first-line treatment for uveal melanoma because it offers the potential for cure, control, and palliation. These factors contribute to the increased adoption and utilization of chemotherapy drugs in managing this condition.

Analysis by Route of Administration

Based on the route of administration, the market is divided into oral and parenteral.

The parenteral segment generated a substantial revenue in the market. The rise in parenteral drugs, such as chemotherapy agents and biologics, is largely due to their effectiveness in delivering high concentrations of medication directly into the bloodstream, which is essential for treating aggressive cancers. Furthermore, the growing number of drug approvals is anticipated to drive the growth of this segment.

• For instance, in January 2022, the FDA approved parenteral tebentafusp-tebn (Kimmtrak), for the patients with metastatic uveal melanoma. This expected to boost the market growth

Analysis by Distribution Channel

Based on distribution channel, the market is subdivided into hospital pharmacies, retail pharmacies, and online pharmacies.

The hospital pharmacies accounted for a significant share in the market. Easy availability of the drugs and increasing number of oncology hospitals are the factors driving the growth of this segment. Additionally, the increasing complexity of cancer treatment necessitates the integration of specialized pharmacy services to optimize medication management and patient outcomes. Moreover, these settings enhances the adherence to treatment regimens, and facilitate timely adjustments in therapy. These factors are driving the segment.

• For instance, in October 2024, Baltimore hospital completed the construction of new oncology hospital with advanced facilities and pharmacies. These new facilities construction is expected boost the diagnosis as well as drug sales in these facilities.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for the largest share of the market in 2023. This dominance is attributed to several key factors, including significant advancements in treatment modalities and a robust healthcare infrastructure that supports the rapid adoption of innovative therapies. The region's ongoing innovations in chemotherapy, targeted therapies, and immunotherapies are anticipated to enhance treatment efficacy and improve patient outcomes, further stimulating market growth throughout the projected period.

Europe ranks as the second-largest market for uveal melanoma therapeutics, with growth driven by a favorable regulatory environment in prominent European nations and increasing investments in research and development. Strategic initiatives within the region are also expected to bolster segment growth.

• For example, in September 2022, F. Hoffmann-La Roche Ltd announced its acquisition of Good Therapeutics, gaining access to innovative platform technologies applicable across various therapeutic areas, including cancer. This initiation advancing treatment options for conditions such as uveal melanoma.

In the Asia Pacific region, improving healthcare infrastructure and rising awareness of cancer are expected to contribute significantly to market growth. Additionally, the region is witnessing an increased emphasis from key players aiming to expand their presence in these emerging markets. The combination of rising healthcare investments and growing public awareness is expected to create new opportunities in the market.

Key Players Covered

The global uveal melanoma therapeutics treatment market is consolidated with few key players.

The report includes the profiles of the following key players:

• GLS Pharma Pvt. Ltd. (Aurobindo Pharma) (India)
• Immunocore Holdings plc (U.K.)
• IDEAYA Biosciences (U.S.)
• Bristol-Myers Squibb Company (U.S.)

Key Industry Developments

• In December 2024, EORTC and Immunocore Holdings plc announced enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma.
• In December 2024, Immunocore Holdings plc announced reimbursement agreement in England for KIMMTRAK for the treatment of metastatic uveal melanoma.